Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer
Disease control
Not yet recruiting
This trial tests whether combining an EGFR-targeted pill (EGFR-TKI) with an antibody-drug conjugate (trastuzumab rezetecan) can shrink tumors in people with advanced non-small cell lung cancer that has both an EGFR mutation and HER2 alterations. Participants receive the combinati…
Phase: PHASE2 • Sponsor: Yongsheng Wang • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC